X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SIS-101-ADO is an siRNA that suppresses the expression of CLCN7, a mutant gene expressed by osteoclasts and other cell types responsible for causing ADO2, the RNA therapy restores bone mass and quality to nearly normal levels.
Lead Product(s): SIS-101-ADO
Therapeutic Area: Musculoskeletal Product Name: SIS-101-ADO
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier sshLNPs and the University of Leipzig’s expertise in miRNA targeting and therapeutic approaches in cancer, with an initial focus on pancreatic cancer to develop miRNA-based Therapies.
Lead Product(s): miR506-3p,miR24-3p
Therapeutic Area: Oncology Product Name: Undislcosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Leipzig
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2023
Details:
SIS-101-ADO combines an siRNA that suppress expression of CLCN7, with SiSaf’s Bio-Courier® next generation silicon stabilized hybrid lipid nanoparticles technology of other RNA delivery technologies by merging LNP technology with inorganic bioabsorbable silicon.
Lead Product(s): SIS-101-ADO
Therapeutic Area: Musculoskeletal Product Name: SIS-101-ADO
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: CSSi LifeSciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
